LA JOLLA, Calif., Feb. 11, 2014 /PRNewswire/ -- StemGenex®, the leading resource for adult adipose stem cell therapy in the US aimed at improving the lives of patients dealing with degenerative diseases, today announced the newest therapy to assist patients diagnosed with COPD.
COPD affects an estimated 9-10% of the world's entire population and is the 4th most common cause of death in the United States. StemGenex believes a new therapy delivering adipose derived mesenchymal cells directly to the inflamed lungs may reduce the complications associated with COPD including shortness of breath, coughing, heart problems and more.
Direct lung targeting is the latest in a series of newly developed therapies StemGenex® has announced over the past few months for patients dealing with degenerative diseases such as Parkinson's, Alzheimer's, Multiple Sclerosis and of course COPD. This targeted therapy is accomplished by nebulizing the stem cells down to a mist so that patients can painlessly breathe the stem cells directly into their lungs. The goal of this new technique is to encourage more stem cells to travel directly to the inflamed tissue of the lungs.
Stem cell treatment studies are currently being offered by StemGenex to patients diagnosed with COPD and degenerative neurological diseases. StemGenex takes a unique approach of compassion and empowerment while providing access to the latest stem cell therapies for degenerative neurological diseases including Parkinson's and Alzheimer's disease, stroke recovery and others. Rita Alexander, founder of StemGenex and the company's first stem cell patient, insists that all patients be treated like they are one of our loved ones. "Hope, compassion, and the relentless pursuit for an end to these diseases are our primary focus."
To find out more about stem cell therapy, contact StemGenex either by phone at (800) 609-7795 or email Contact@stemgenex.com.
Multimedia Assets associated with this release: